Solving COVID
January 5, 2021

The Food and Drug Administration has shot down suggestions to change COVID-19 vaccine regimens "at this time."

FDA officials in a statement rejected for the time being numerous ideas that have been floated amid the slow U.S. vaccine rollout, including halving doses or delaying second doses so more people can receive the first one sooner, Axios reports.

"We have been following the discussions and news reports about reducing the number of doses, extending the length of time between doses, changing the dose (half-dose), or mixing and matching vaccines in order to immunize more people against COVID-19," the FDA said. "These are all reasonable questions to consider and evaluate in clinical trials. However, at this time, suggesting changes to the FDA-authorized dosing or schedules of these vaccines is premature and not rooted solidly in the available evidence."

The FDA officials go on to say that making changes of this kind "without appropriate data" could place "public health at risk," and the data "continue to support" administering Pfizer and Moderna vaccine doses at the previously-specified intervals.

Operation Warp Speed chief adviser Dr. Moncef Slaoui previously said the U.S. was looking at potentially administering two half doses of Moderna's vaccine to some Americans in order to immunize "double the number of people with the doses we have." And officials in Britain have said "they will allow more than 21 days between doses of Pfizer's vaccines and would consider allowing people to get vaccinated with two different vaccines," CNN reports.

But Dr. Anthony Fauci, the nation's top infectious disease expert, said Monday "there really are no data on what happens if you delay the second dose by three months or four months or two months," per The Washington Post. He added, "It's fraught with some danger when you're making a decision about the regimen you're going to use when you don't really have a considerable amount of data." Brendan Morrow

January 14, 2021

Contracting COVID-19 is nearly as effective at preventing reinfection as the two top coronavirus vaccines — but there are a few catches.

A study by Public Health England, which has yet to be peer reviewed, tested 21,000 health-care workers across the U.K. and found 6,614 of them had antibodies against COVID-19, indicating they'd contracted the virus in the past. But of those who'd been infected, 44 had possibly gotten the virus again despite their antibodies, indicating an 83 percent chance of protection against reinfection over five months, CNN reports.

As Forbes notes, 83 percent isn't far off from the 95 percent effectiveness provided by Moderna's vaccine, or the 94 percent from Pfizer's. Still, that percentage means it's very possible for people who've gotten the virus to contract it again, the study notes. That fact has been proven over the past year as people who've recovered from COVID-19 have tested positive for it again months later. Researchers also found those who were seemingly immune to the virus may still carry it around and transmit it to other people, showing why it's still important to wear a mask and take other precautions regardless of past infections or vaccination.

The study will keep monitoring the workers for a year to determine just how long the antibody protections last. Kathryn Krawczyk

January 14, 2021

Johnson & Johnson's coronavirus vaccine proved safe and provoked an immune response in young and elderly volunteers alike, according to trial results published Wednesday in the New England Journal of Medicine. Most trial participants got just one shot of a high or low vaccine dose, or a placebo, although some people aged 18 to 55 got two doses. Most of the volunteers who got the vaccine produced the neutralizing antibodies, which defend cells from the virus, after 28 days. Researchers reported some side effects, including fever, fatigue, headache, and pain at the injection site. Dr. Paul Stoffels, chief scientific officer at J&J, said the data gave the company "confidence" the vaccine will prove highly effective. Results from the larger phase-three trial are expected later this month. Harold Maass

January 13, 2021

Britain on Tuesday began a large-scale trial of a new COVID-19 treatment in which patients inhale aerosolized interferon beta proteins into the lungs with a nebulizer. The treatment, developed at Southampton University Hospital and produced by biotech firm Synairgen, cut the odds of COVID-19 patients developing severe symptoms by nearly 80 percent, according to a small, phase 2 trial of 100 patients. The new phase 3 study involves more than 600 subjects in 20 countries, half of whom will get the treatment and half a placebo inhalant.

The body produces interferon beta to fight off viral infections, but the new coronavirus appears to suppress production of the proteins as part of its mechanism to evade patients' immune responses, BBC News reports. Synairgen hopes a direct shot of aerosolized interferon beta straight to the lungs will provoke a strong anti-viral response. The early results are promising, but experts warn that promising treatments don't always pan out.

"We've had other drugs in similar circumstances, we've had hydroxychloroquine, for example," Dr. Lamis Latif tells BBC News. "But again, when that reached further trials, it wasn't as promising as it initially made up to be. Peter Weber

January 12, 2021

Millions of Americans are on their way to getting vaccinated for the virus, as well as many more people around the world. But despite the fact that slow vaccine rollouts mean the U.S. won't achieve herd immunity for months to come, a study published Tuesday in Science also suggests COVID-19 is "here to stay," The New York Times reports.

Right now, COVID-19 is incredibly dangerous and often deadly because it's brand new to the human body. But once people's immune systems are introduced to the virus, either by contracting it or, hopefully, through a vaccine, they'll get better at fighting the virus off. Things are different for children, who have strong immune systems because they're constantly experiencing viruses and pathogens that are new to their bodies. For example, they start contracting common cold coronaviruses at around age 3 to 5 and fight them off, building up immunity as they're infected again and again over the years.

So after most Americans are vaccinated, severe coronavirus infections will likely still happen — albeit rarely — among adults. Then, years or decades later, those severe reactions will likely peter out due to increased immunity among adults, Jennie Lavine, a postdoctoral fellow at Emory University, who led the study, told the Times. That's when COVID-19 will likely join the league of endemic coronaviruses that cause the common cold, Lavine and her team predicted after comparing COVID-19 to other coronaviruses. And again, because of the immunity adults have picked up, COVID-19 will likely only infect children under five years old — and they'll probably only end up with some sniffles or no symptoms at all.

Read more at The New York Times and find the whole study at Science. Kathryn Krawczyk

January 12, 2021

Israel is planning to provide COVID-19 vaccines to Holocaust survivors, both within the country and across the diaspora, Israel Hayom reports, per The Jerusalem Post.

The operation is reportedly in the early stages — Israel's Diaspora Affairs Minister Omer Yankelevich has instructed the Shalom Corps to strategize, and the group has reportedly approached large medical shipping companies about logistics. Meanwhile, the diaspora affairs ministry is reportedly working with Israel's health ministry to coordinate with Pfizer and Moderna, the companies producing coronavirus vaccines authorized in Israel. The intention is reportedly to provide survivors around the world with additional vaccines, rather than take from Israel's quota.

"In a time of acute global crisis in the face of the coronavirus, we have the privilege to repay, if only slightly, Holocaust survivors who survived the inferno of Nazi oppression," Yankelevich told Israel Hayom.

Israel has received international praise for its vaccination program, which includes inoculating roughly 150,000 people, or a world-leading 1.5 percent of the population, per day, putting the country on pace to complete the mission within a matter of months. At the same time, Jerusalem has faced criticism for not distributing vaccines to Palestinians living in the West Bank and Gaza, instead contending the Palestinian Authority holds that responsibility. Read more about the plan to vaccinate Holocaust survivors around the world at The Jerusalem Post. Tim O'Donnell

January 12, 2021

As the United States' COVID-19 vaccination efforts get off to a slow start, the Trump administration will reportedly issue some key new guidelines to states.

The federal government is set to make "three big changes" to its COVID-19 vaccination guidelines, Axios reported on Tuesday, citing an administration official. The first will be recommending states "open the vaccination process to everyone older than 65 and to adults of all ages who have a pre-existing condition that puts them at greater risk for serious infection," Axios reports.

Additionally, Axios reports the Trump administration will seek to expand the venues where Americans can receive vaccinations. Finally, the government will recommend no longer holding back doses to ensure all Americans can receive a second shot, according to Axios. President-elect Joe Biden's transition previously announced plans to release almost all available vaccine doses.

News of the recommendations was confirmed by Bloomberg and The Associated Press. They come amid a slow COVID-19 vaccine rollout in the U.S., as the Centers for Disease Control and Prevention says about 9 million Americans have received a dose of a coronavirus vaccine, according to The New York Times. The Trump administration's goal was for 20 million Americans to receive a vaccine dose by the end of 2020. Brendan Morrow

January 11, 2021

BioNTech, the German biotechnology firm that partnered with Pfizer to produce one of the two COVID-19 vaccines authorized for emergency use in the United States, is upping its 2021 vaccine delivery target to 2 billion doses, the company announced Monday.

Previously, the goal was to distribute 1.3 billion doses, but the use of a special syringe that allows six doses, rather than five, to be extracted from a standard vaccine vial was a driving force in raising the bar, Reuters reports. A new production site in Marburg, Germany, will become operational at the end of February and additional capacity by contractors supplying ingredients and filling the finished substance into vials will contribute to the new distribution goal. Read more at Reuters. Tim O'Donnell

January 9, 2021

President-elect Joe Biden plans to release nearly every available dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines when he takes office later this month rather than holding back millions of second doses, his transition team said Friday. The decision is meant to "ensure the Americans who need it most get it as soon as possible."

The Trump administration has insisted it's necessary to retain second doses, with Health and Human Services Secretary Alex Azar on Friday expressing concern that Biden's plan could backfire if there are any manufacturing mishaps.

Outside of the White House, Dr. Leana Wen of George Washington University, was also apprehensive, noting that there is "an ethical consideration" since those who volunteered for the initial dose were reasonably expecting to receive the second in the proper amount of time. Biden does not intend to delay the second shot for those patients, and is instead counting on an increased production to keep pace. But, Wen says, not only is there no guarantee of a smooth manufacturing process, much of the slowdown has occurred between distribution and injection, so until that stage improves the risk of delay remains.

Harvard University's Juliette Kayyem, however, is more on board with the plan. She believes it's unlikely there will be a supply problem and is encouraged by recent upticks in actual vaccinations. Tim O'Donnell

See More Speed Reads